- Report
- May 2024
- 170 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- September 2024
- 78 Pages
Global
From €3265EUR$3,495USD£2,762GBP
- Report
- October 2024
- 193 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- May 2024
- 136 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- June 2024
- 200 Pages
Global
From €7427EUR$7,950USD£6,283GBP
- Report
- March 2024
- 150 Pages
Global
From €4531EUR$4,850USD£3,833GBP
- Report
- January 2022
- 60 Pages
Global
From €3690EUR$3,950USD£3,122GBP
- Report
- March 2023
- 147 Pages
Global
From €4623EUR$4,949USD£3,911GBP
- Report
- April 2023
- 110 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- October 2023
- 207 Pages
Global
From €2336EUR$2,500USD£1,976GBP
- Report
- August 2022
Global
From €738EUR$790USD£624GBP
- Report
- October 2023
- 96 Pages
Global
From €3500EUR$4,013USD£3,065GBP
The Gonorrhea Drug market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat a variety of bacterial, viral, and fungal infections. Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. Treatment for gonorrhea typically involves antibiotics, such as cephalosporins, macrolides, and fluoroquinolones. These drugs are used to reduce the symptoms of the infection and prevent further spread.
The market for Gonorrhea Drugs is highly competitive, with a number of major pharmaceutical companies offering products. These companies include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, and Bayer. Additionally, there are a number of smaller companies that specialize in the development and manufacture of Gonorrhea Drugs. Show Less Read more